113
Participants
Start Date
November 18, 2015
Primary Completion Date
October 25, 2016
Study Completion Date
December 1, 2020
Emicizumab
Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
rFVIIa
Participants will continue to receive rFVIIa.
aPCC
Participants will continue to receive aPCC.
ICIC, San José
Auckland City Hospital; Auckland Haemophilia Centre, Auckland
Royal Prince Alfred Hospital; Haematology, Camperdown
Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center, Johannesburg
The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit, Melbourne
Cornell Univ Medical College; Hematology-Oncolog, New York
National Taiwan Uni Hospital, Taipei
"IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi Angelo Bianchi e Bonomi", Milan
CTC North GmbH & Co. KG am Universitätsklinikum Hamburg-Eppendorf, Hamburg
Hospital Universitario la Paz; Servicio de Hematologia, Madrid
Winship Cancer Institute, Atlanta
Hospital Universitario Virgen del Rocio; Servicio de Hematologia, Seville
Hospital Universitario la Fe; Servicio de Hematologia, Valencia
Children's Hospital of Michigan; Pediatrics, Detroit
AOU Careggi; SOD Malattie Emorragiche, Florence
Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn
Hopital Cardiologique; Hematologie B, Lille
Hämophilie-Zentrum Rhein Main GmbH, Mörfelden-Walldorf
Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique, Bron
Groupe Hospitalier Necker Enfants Malades, Paris
Univ of TX Health Science Ctr; Gulf States Hemo and Throm Ctr, Houston
University of Colorado Denver, Children's Hospital, Aurora
Children's Hospital Los Angeles, Los Angeles
Santa Monica Oncology Center, Santa Monica
CH de Bicetre; Centre de Traitement d' Hemophilie, Le Kremlin-Bicêtre
Oregon Health & Science Uni ; Dept of Pediatrics, Portland
Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia, Seattle
Boston Childrens Hospital, Boston
Pennsylvania State Hershey Medical Center; Division of Hematology/Oncology, H046, Hershey
Nagoya University Hospital, Aichi
Hiroshima University Hospital, Hiroshima
Hyogo College of Medicine Hospital, Hyōgo
St. Marianna University School of Medicine Hospital, Kanagawa
Hospital of the University of Occupational and Environmental Health,Japan, Kitakyushu-shi
Nara Medical University Hospital, Nara
Tokyo Medical University Hospital, Tokyo
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk
SPSK Nr1 Klinika Hematoo&Transpl.Szpiku, Lublin
ALVAMED Lekarskie Gabinety Specjalistyczne, Poznan
Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych, Warsaw
Severance Hospital, Seoul
Cardiff and Vale NHS Trust, Cardiff
St Thomas' Hospital; Haemostasis & Thromboisis Centre, London
Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford
Collaborators (1)
Chugai Pharmaceutical
INDUSTRY
Hoffmann-La Roche
INDUSTRY